Virpax Pharmaceuticals Inc - VRPX STOCK NEWS

Virpax Pharmaceuticals will present virtually at the H.C. Wainwright BioConnect Virtual Conference from January 10 to January 13, starting at 7:00 a.m. ET. CEO Anthony Mack will lead the presentation, with one-on-one meetings available on January 10 and 11. Participants can watch the presentation on-demand daily until 7:00 p.m. ET and access a replay for 90 days on the company’s website. Virpax focuses on non-addictive pain management and neurological disorders, aiming for FDA approval of several innovative drug delivery systems.

Virpax Pharmaceuticals (NASDAQ: VRPX) has made notable strides in its product pipeline as of 2021. The company anticipates starting initial human trials for Epoladerm in Q2 2022. Key advancements include the development of AnQlar, an OTC antiviral candidate, and VRP324, a CBD formulation for epilepsy. Additionally, Virpax appointed new board members and raised approximately $58 million from IPOs, enhancing its R&D funding. Epoladerm’s toxicology study showed it was well-tolerated in minipigs. The company intends to conduct Phase 1 studies for Epoladerm in Canada soon.

Virpax Pharmaceuticals (NASDAQ: VRPX) has entered into a clinical trial agreement with Altasciences for a First in Human study of Epoladerm™, targeting pain associated with osteoarthritis of the knee. The trial, set to commence in Canada, aims to enroll its first patient by Q2 2022. Epoladerm™ is a topical spray film designed to provide a non-addictive solution for chronic pain. The data generated will support regulatory filings for FDA approval under the 505(b)(2) pathway, enhancing Virpax's portfolio for non-addictive pain management.

Virpax Pharmaceuticals (NASDAQ: VRPX) announced successful toxicology and pharmacokinetic study results for Epoladerm™, aimed at managing knee osteoarthritis pain. Conducted by Charles River Laboratories, the study demonstrated that Epoladerm was well-tolerated, with no adverse effects observed in minipigs. Plasma levels confirmed effective transdermal absorption, peaking at four hours post-dose and remaining detectable after 24 hours. These findings are expected to bolster the Company’s IND filing, paving the way for upcoming first-in-human clinical trials.

Virpax Pharmaceuticals (NASDAQ:VRPX) reported its financial results for Q3 and YTD 2021, highlighting a $40 million public offering that bolstered its balance sheet. The company aims to expedite its product pipeline, focusing on indications for pain, CNS disorders, and antiviral applications. Cash reserves stand at $41.7 million, enabling progress on IND filings for candidates like Epoladerm and Envelta. Operating losses grew to $3.2 million for Q3, up from $1.7 million a year prior, driven by rising operating expenses.

Virpax Pharmaceuticals (NASDAQ: VRPX) has announced the award of research and development contracts by the National Center for Advancing Translational Sciences (NCATS) to support the Good Manufacturing Practices (GMP) production of its drug Envelta. This includes the procurement of devices for preclinical studies and the manufacturing of the active ingredient L-ENK. Envelta is designed for pain management and is part of Virpax’s ongoing development efforts for non-addictive pain relief alternatives. The company plans to submit an IND package to the FDA to initiate human trials once the studies are completed.

Virpax Pharmaceuticals (NASDAQ: VRPX) announced an agreement with Sinclair Research to conduct preclinical studies of AnQlar™, an over-the-counter prophylactic aimed at combating SARS and influenza. These studies will assess method, dosage, and toxicity for an Investigational New Drug Application, expected to commence in January 2022. CEO Anthony Mack emphasized the significance of this step in advancing their anti-viral pipeline. AnQlar is a chitosan derivative that may inhibit viral replication and entry into cells, showcasing potential in managing viral infections.

Virpax Pharmaceuticals (NASDAQ: VRPX), focused on pain management and CNS disorders, announced that its Chairman and CEO, Anthony P. Mack, will present at the Pain Management Virtual Investor Forum on October 7, 2021, at 9:00 a.m. Eastern time. The event will be moderated by Gregory Aurand from Noble Capital Markets. Registration is free, and the presentation will be archived on Channelchek and Virpax's investor page. Virpax is known for its non-addictive pain management products and is pursuing FDA approval for innovative drug delivery systems.

Virpax Pharmaceuticals (NASDAQ:VRPX) has acquired exclusive global rights to Nanomerics' molecular envelope platform technology for the nasal delivery of cannabidiol (CBD) aimed at managing epilepsy in patients aged one year and older. The investigational product, VRP324, will utilize a unique device for intranasal CBD transport, targeting severe epilepsy syndromes. Preclinical studies are underway, and successful results may lead to an FDA application. This acquisition marks a strategic expansion into neurology, enhancing Virpax's innovative drug delivery platforms.